@article { author = {}, title = {Systematic Analysis of Pemetrexed-based Chemoradiotherapy for Patients with Locally Advanced or Metastatic Esophageal Cancer}, journal = {Asian Pacific Journal of Cancer Prevention}, volume = {15}, number = {19}, pages = {8475-8478}, year = {2014}, publisher = {West Asia Organization for Cancer Prevention (WAOCP), APOCP's West Asia Chapter.}, issn = {1513-7368}, eissn = {2476-762X}, doi = {}, abstract = {Purpose: This systematic analysis was conducted to evaluate the efficacy and safety of pemetrexed-basedchemoradiotherapy in treating patients with locally advanced or metastatic esophageal cancer. Methods: Clinicalstudies evaluating the efficacy and safety of pemetrexed based regimens on response and safety for relevant patientswere identified using a predefined search strategy. Pooled response rates (RRs) were calculated. Results: Forpemetrexed-based regimens, 4 clinical studies including 47 patients with locally advanced or metastatic esophagealcancer were considered eligible for inclusion. Systematic analysis showed that, in all patients, the pooled RR was51% (24/47) . Major adverse effects of grade III/IV were esophagitis, neutropenia, thrombocytopenia, anemiaanorexia, fatigue, diarrhea, dysphagia and vomiting. No treatment related death occurred with pemetrexed-basedtreatment. Conclusion: This systematic analysis suggests that pemetrexed based radiotherapy is associated withreasonable activity and good tolerability in treating patients with locally advanced or metastatic esophagealcancer.}, keywords = {Metastatic esophageal cancer,pemetrexed-based chemoradiotherapy,Efficacy,tolerability}, url = {https://journal.waocp.org/article_29945.html}, eprint = {https://journal.waocp.org/article_29945_fac73db956ad96263bdb025849300aef.pdf} }